drugset
drugset / Trial / NCT07240675

Single-dose,First-in-human of KLA478

NCT07240675 ↗

Phase 1 Recruiting 40 enrolled Hunan Kelun Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single doses of KLA478 in healthy volunteers；

Timeline

Start
2025-11-26
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject KLA478 Unknown 2 mg Intramuscular
Subject KLA478 Unknown 5 mg Intramuscular
Subject KLA478 Unknown 10 mg Intramuscular
Comparator Pramipexole Unknown 0.375 mg Oral

Indications

No indication recorded.